Alloimmunization in Congenital Deficiencies of Platelet Surface Glycoproteins: Focus on Glanzmann's Thrombasthenia and Bernard–Soulier's Syndrome

Man-Chiu Poon; Roseline d'Oiron

doi:10.1055/s-0038-1648233

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2018; 44(06): 604-614
DOI: 10.1055/s-0038-1648233

Review Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Alloimmunization in Congenital Deficiencies of Platelet Surface Glycoproteins: Focus on Glanzmann's Thrombasthenia and Bernard–Soulier's Syndrome

Authors

Man-Chiu Poon

¹Department of Medicine, Cumming School of Medicine, University of Calgary and Southern Alberta Rare Blood and Bleeding Disorders Comprehensive Care Program, Calgary, Alberta, Canada
Roseline d'Oiron

²Centre de Traitement de l'Hémophilie et autres Maladies Hémorragiques Constitutionnelles Rares, Hôpitaux Universitaires Paris Sud APHP - Hôpital Bicêtre APHP, Le Kremlin-Bicêtre, France

Abstract

Glanzmann's thrombasthenia (GT) and Bernard–Soulier's syndrome (BSS) are well-understood congenital bleeding disorders, showing defect/deficiency of platelet glycoprotein (GP) IIb/IIIa (integrin αIIbβ3) and GPIb-IX-V complexes respectively, with relevant clinical, laboratory, biochemical, and genetic features. Following platelet transfusion, affected patients may develop antiplatelet antibodies (to human leukocyte antigen [HLA], and/or αIIbβ3 in GT or GPIb-IX in BSS), which may render future platelet transfusion ineffective. Anti-αIIbβ3 and anti-GPIb-IX may also cross the placenta during pregnancy to cause thrombocytopenia and bleeding in the fetus/neonate. This review will focus particularly on the better studied GT to illustrate the natural history and complications of platelet alloimmunization. BSS will be more briefly discussed. Platelet transfusion, if unavoidable, should be given judiciously with good indications. Patients following platelet transfusion, and women during and after pregnancy, should be monitored for the development of platelet antibodies. There is now a collection of data suggesting the safety and effectiveness of recombinant activated factor VII in the management of affected patients with platelet antibodies.

Keywords

Glanzmann's thrombasthenia - Bernard–Soulier's syndrome - platelet transfusion - alloimmunization - platelet antibodies - HLA antibodies - αIIbβ3 (GPIIb/IIIa) antibodies - GPIb-IX antibodies - rFVIIa - pregnancy

Full Text

References

References
1 George JN, Caen JP, Nurden AT. Glanzmann's thrombasthenia: the spectrum of clinical disease. Blood 1990; 75 (07) 1383-1395
2 Toogeh G, Sharifian R, Lak M, Safaee R, Artoni A, Peyvandi F. Presentation and pattern of symptoms in 382 patients with Glanzmann thrombasthenia in Iran. Am J Hematol 2004; 77 (02) 198-199
3 Bennett JS, Vilaire G. Exposure of platelet fibrinogen receptors by ADP and epinephrine. J Clin Invest 1979; 64 (05) 1393-1401
4 Patel D, Väänänen H, Jirousková M, Hoffmann T, Bodian C, Coller BS. Dynamics of GPIIb/IIIa-mediated platelet-platelet interactions in platelet adhesion/thrombus formation on collagen in vitro as revealed by videomicroscopy. Blood 2003; 101 (03) 929-936
5 Nurden AT, Fiore M, Nurden P, Pillois X. Glanzmann thrombasthenia: a review of ITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models. Blood 2011; 118 (23) 5996-6005
6 Fiore M, Firah N, Pillois X, Nurden P, Heilig R, Nurden AT. Natural history of platelet antibody formation against αIIbβ3 in a French cohort of Glanzmann thrombasthenia patients. Haemophilia 2012; 18 (03) e201-e209
7 D'Andrea G, Colaizzo D, Vecchione G, Grandone E, Di Minno G, Margaglione M. ; GLAnzmann's Thrombasthenia Italian Team (GLATIT). Glanzmann's thrombasthenia: identification of 19 new mutations in 30 patients. Thromb Haemost 2002; 87 (06) 1034-1042
8 Nurden AT, Pillois X, Fiore M. , et al. Expanding the mutation spectrum affecting αIIbβ3 integrin in Glanzmann thrombasthenia: screening of the ITGA2B and ITGB3 genes in a large international cohort. Hum Mutat 2015; 36 (05) 548-561
9 Jennings LK, Ashmun RA, Wang WC, Dockter ME. Analysis of human platelet glycoproteins IIb-IIIa and Glanzmann's thrombasthenia in whole blood by flow cytometry. Blood 1986; 68 (01) 173-179
10 Ginsberg MH, Frelinger AL, Lam SC. , et al. Analysis of platelet aggregation disorders based on flow cytometric analysis of membrane glycoprotein IIb-IIIa with conformation-specific monoclonal antibodies. Blood 1990; 76 (10) 2017-2023
11 Kashiwagi H, Kunishima S, Kiyomizu K. , et al. Demonstration of novel gain-of-function mutations of αIIbβ3: association with macrothrombocytopenia and Glanzmann thrombasthenia-like phenotype. Mol Genet Genomic Med 2013; 1 (02) 77-86
12 D'Andrea G, Margaglione M. ; Glansmann's Thrombasthemia Italian Team (GLATIT). Glanzmann's thrombasthenia: modulation of clinical phenotype by alpha2C807T gene polymorphism. Haematologica 2003; 88 (12) 1378-1382
13 Di Minno G, Zotz RB, d'Oiron R, Bindslev N, Di Minno MN, Poon MC. ; Glanzmann Thrombasthenia Registry Investigators. The international, prospective Glanzmann Thrombasthenia Registry: treatment modalities and outcomes of non-surgical bleeding episodes in patients with Glanzmann thrombasthenia. Haematologica 2015; 100 (08) 1031-1037
14 Poon MC, d'Oiron R, Zotz RB, Bindslev N, Di Minno MN, Di Minno G. ; Glanzmann Thrombasthenia Registry Investigators. The international, prospective Glanzmann Thrombasthenia Registry: treatment and outcomes in surgical intervention. Haematologica 2015; 100 (08) 1038-1044
15 Poon MC, Di Minno G, d'Oiron R, Zotz R. New insights into the treatment of Glanzmann thrombasthenia. Transfus Med Rev 2016; 30 (02) 92-99
16 Poon M-C, Di Minno D, Zotz R, d'Oiron R. Glanzmann's thrombasthenia: strategies for identification and management. Expert Opin Orphan Drugs 2017; 5 (08) 641-653
17 Poon MC, Demers C, Jobin F, Wu JW. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. Blood 1999; 94 (11) 3951-3953
18 Srivastava A, Brewer AK, Mauser-Bunschoten EP. , et al; Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia. Guidelines for the management of hemophilia. Haemophilia 2013; 19 (01) e1-e47
19 Carson JL, Guyatt G, Heddle NM. , et al. Clinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage. JAMA 2016; 316 (19) 2025-2035
20 Vamvakas EC, Blajchman MA. Blood still kills: six strategies to further reduce allogeneic blood transfusion-related mortality. Transfus Med Rev 2010; 24 (02) 77-124
21 Laurian Y, Tisseron-Maury B, Bibi Triki T, Kaplan C, Gaudelus J. Red blood cell transfusion in patients with type 1 Glanzmann's thrombasthenia. J Thromb Haemost 2005; 3 (10) 2346-2347
22 Siddiq S, Clark A, Mumford A. A systematic review of the management and outcomes of pregnancy in Glanzmann thrombasthenia. Haemophilia 2011; 17 (05) e858-e869
23 Santoro C, Rago A, Biondo F. , et al. Prevalence of allo-immunization anti-HLA and anti-integrin alphaIIbbeta3 in Glanzmann Thromboasthenia patients. Haemophilia 2010; 16 (05) 805-812
24 Poon MC, D'Oiron R, Von Depka M. , et al; International Data Collection on Recombinant Factor VIIa and Congenital Platelet Disorders Study Group. Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey. J Thromb Haemost 2004; 2 (07) 1096-1103
25 Rebulla P. A mini-review on platelet refractoriness. Haematologica 2005; 90 (02) 247-253
26 Hod E, Schwartz J. Platelet transfusion refractoriness. Br J Haematol 2008; 142 (03) 348-360
27 Slichter SJ. ; Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997; 337 (26) 1861-1869
28 Laundy GJ, Bradley BA, Rees BM, Younie M, Hows JM. Incidence and specificity of HLA antibodies in multitransfused patients with acquired aplastic anemia. Transfusion 2004; 44 (06) 814-825
29 Santoso S, Kalb R, Kiefel V, Mueller-Eckhardt C. The presence of messenger RNA for HLA class I in human platelets and its capability for protein biosynthesis. Br J Haematol 1993; 84 (03) 451-456
30 Claas FH, Smeenk RJ, Schmidt R, van Steenbrugge GJ, Eernisse JG. Alloimmunization against the MHC antigens after platelet transfusions is due to contaminating leukocytes in the platelet suspension. Exp Hematol 1981; 9 (01) 84-89
31 British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of platelet transfusions. Br J Haematol 2003; 122 (01) 10-23
32 Alamelu J, Liesner R. Modern management of severe platelet function disorders. Br J Haematol 2010; 149 (06) 813-823
33 Kiefel V, Santoso S, Weisheit M, Müeller-Eckhardt C. Monoclonal antibody--specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies. Blood 1987; 70 (06) 1722-1726
34 Martin I, Kriaa F, Proulle V. , et al. Protein A sepharose immunoadsorption can restore the efficacy of platelet concentrates in patients with Glanzmann's thrombasthenia and anti-glycoprotein IIb-IIIa antibodies. Br J Haematol 2002; 119 (04) 991-997
35 Porcelijn L, Huiskes E, Comijs-van Osselen I. , et al. A new bead-based human platelet antigen antibodies detection assay versus the monoclonal antibody immobilization of platelet antigens assay. Transfusion 2014; 54 (06) 1486-1492
36 Bierling P, Fromont P, Elbez A, Duedari N, Kieffer N. Early immunization against platelet glycoprotein IIIa in a newborn Glanzmann type I patient. Vox Sang 1988; 55 (02) 109-113
37 Léticée N, Kaplan C, Lémery D. Pregnancy in mother with Glanzmann's thrombasthenia and isoantibody against GPIIb-IIIa: is there a foetal risk?. Eur J Obstet Gynecol Reprod Biol 2005; 121 (02) 139-142
38 Jennings LK, Wang WC, Jackson CW, Fox CF, Bell A. Hemostasis in Glanzmann's thrombasthenia (GT): GT platelets interfere with the aggregation of normal platelets. Am J Pediatr Hematol Oncol 1991; 13 (01) 84-90
39 Al-Battat S, Rand ML, Bouskill V. , et al. Glanzmann thrombasthenia platelets compete with transfused platelets, reducing the haemostatic impact of platelet transfusions. Br J Haematol 2017
40 Hess JR, Trachtenberg FL, Assmann SF. , et al. Clinical and laboratory correlates of platelet alloimmunization and refractoriness in the PLADO trial. Vox Sang 2016; 111 (03) 281-291
41 Nurden A, Combrié R, Nurden P. Detection of transfused platelets in a patient with Glanzmann thrombasthenia. Thromb Haemost 2002; 87 (03) 543-544
42 Ito K, Yoshida H, Hatoyama H. , et al. Antibody removal therapy used successfully at delivery of a pregnant patient with Glanzmann's thrombasthenia and multiple anti-platelet antibodies. Vox Sang 1991; 61 (01) 40-46
43 Boval B, Bellucci S, Boyer-Neumann C. , et al. Glanzmann thrombasthenia and pregnancy: clinical observations and management of four affected women. J Thromb Haemost 2001
44 Jallu V, Pico M, Chevaleyre J, Vézon G, Kunicki TJ, Nurden AT. Characterization of an antibody to the integrin beta 3 subunit (GP IIIa) from a patient with neonatal thrombocytopenia and an inherited deficiency of GP IIb-IIIa complexes in platelets (Glanzmann's thrombasthenia). Hum Antibodies Hybridomas 1992; 3 (02) 93-106
45 Jallu V, Diaz-Ricart M, Ordinas A, Pico M, Vezon G, Nurden AT. Two human antibodies reacting with different epitopes on integrin beta 3 of platelets and endothelial cells. Eur J Biochem 1994; 222 (03) 743-751
46 Wihadmadyatami H, Röder L, Berghöfer H. , et al. Immunisation against αIIbβ3 and αvβ3 in a type 1 variant of Glanzmann's thrombasthenia caused by a missense mutation Gly540Asp on β3. Thromb Haemost 2016; 116 (02) 262-271
47 Zdravic D, Yougbare I, Vadasz B. , et al. Fetal and neonatal alloimmune thrombocytopenia. Semin Fetal Neonatal Med 2016; 21 (01) 19-27
48 Neufeld EJ, Négrier C, Arkhammar P. , et al. Safety update on the use of recombinant activated factor VII in approved indications. Blood Rev 2015; 29 (Suppl. 01) S34-S41
49 Hoffman M, Monroe III DM, Roberts HR. Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis 1998; 9 (Suppl. 01) S61-S65
50 Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99 (03) 542-547
51 Weeterings C, de Groot PG, Adelmeijer J, Lisman T. The glycoprotein Ib-IX-V complex contributes to tissue factor-independent thrombin generation by recombinant factor VIIa on the activated platelet surface. Blood 2008; 112 (08) 3227-3233
52 Lisman T, Adelmeijer J, Heijnen HF, de Groot PG. Recombinant factor VIIa restores aggregation of alphaIIbbeta3-deficient platelets via tissue factor-independent fibrin generation. Blood 2004; 103 (05) 1720-1727
53 Lisman T, Moschatsis S, Adelmeijer J, Nieuwenhuis HK, De Groot PG. Recombinant factor VIIa enhances deposition of platelets with congenital or acquired alpha IIb beta 3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation. Blood 2003; 101 (05) 1864-1870
54 He S, Blombäck M, Jacobsson Ekman G, Hedner U. The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX. J Thromb Haemost 2003; 1 (06) 1215-1219
55 He S, Ekman GJ, Hedner U. The effect of platelets on fibrin gel structure formed in the presence of recombinant factor VIIa in hemophilia plasma and in plasma from a patient with Glanzmann thrombasthenia. J Thromb Haemost 2005; 3 (02) 272-279
56 Dargaud Y, Bordet JC, Trzeciak MC, Vinciguerra C, Negrier C. A case of Glanzmann's thrombasthenia successfully treated with recombinant factor VIIa during a surgical procedure: observations on the monitoring and the mechanism of action of this drug. Haematologica 2006; 91 (6, Suppl): ECR20
57 Lopez-Vilchez I, Hedner U, Altisent C, Diaz-Ricart M, Escolar G, Galan AM. Redistribution and hemostatic action of recombinant activated factor VII associated with platelets. Am J Pathol 2011; 178 (06) 2938-2948
58 Proulle V, Hugel B, Guillet B. , et al. Injection of recombinant activated factor VII can induce transient increase in circulating procoagulant microparticles. Thromb Haemost 2004; 91 (05) 873-878
59 Nurden AT, Freson K, Seligsohn U. Inherited platelet disorders. Haemophilia 2012; 18 (Suppl. 04) 154-160
60 Peng TC, Kickler TS, Bell WR, Haller E. Obstetric complications in a patient with Bernard-Soulier syndrome. Am J Obstet Gynecol 1991; 165 (02) 425-426
61 Peitsidis P, Datta T, Pafilis I, Otomewo O, Tuddenham EG, Kadir RA. Bernard Soulier syndrome in pregnancy: a systematic review. Haemophilia 2010; 16 (04) 584-591
62 Almeida AM, Khair K, Hann I, Liesner R. The use of recombinant factor VIIa in children with inherited platelet function disorders. Br J Haematol 2003; 121 (03) 477-481
63 Ozelo MC, Svirin P, Larina L. Use of recombinant factor VIIa in the management of severe bleeding episodes in patients with Bernard-Soulier syndrome. Ann Hematol 2005; 84 (12) 816-822
64 Tefre KL, Ingerslev J, Sørensen B. Clinical benefit of recombinant factor VIIa in management of bleeds and surgery in two brothers suffering from the Bernard-Soulier syndrome. Haemophilia 2009; 15 (01) 281-284